Online first
Review article
Published online: 2024-11-25
2024 ESC Guidelines on the treatment of chronic coronary syndrome — unanswered questions regarding antianginal medical therapy recommendations. A position paper of the ELECTRA-SIRIO 2 investigators
123
, 1, 45, 1, 6, 7, 89, 10, 11, 12, 13, 14, 15, 2, 163, 17, 16, 18, 19, 16, 20, 21, 22, 16, 16, 162, 16, 1, 23, 24, 25, 16, 2627, ,
, 1, 45, 1, 6, 7, 89, 10, 11, 12, 13, 14, 15, 2, 163, 17, 16, 18, 19, 16, 20, 21, 22, 16, 16, 162, 16, 1, 23, 24, 25, 16, 2627, ,
DOI: 10.5603/mrj.103601
Abstract
According to the 2024 ESC guidelines for the management of chronic coronary syndrome antianginal
medical therapy aims to control symptoms while ensuring acceptable tolerability and patient adherence.
The guidelines specify the indications for particular groups of antianginal drugs, defining the class of
indications and the level of evidence based on the results of expert opinions, registries, clinical studies,
and meta-analyses. This very important document has a great impact on clinical practice as it constitutes
the basis for therapeutic decisions. Therefore, it is worth understanding the assumptions that guided the
authors when formulating specific recommendations. As the investigators of the ELCTRA -SIRIO 2 trial*,
we are monitoring new scientific evidence and new guidelines that may impact our study protocol.
Keywords: chronic coronary syndromeantianginal medication
References
- Vrints C, Andreotti F, Koskinas KC, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024; 45(36): 3415–3537.
- Ferrari R, Pavasini R, Camici PG, et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019; 40(2): 190–194.
- Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
- Kubica J, Adamski P, Niezgoda P, et al. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020; 27(6): 661–676.
- Adamski P, Ostrowska M, Navarese EP, et al. Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease. Curr Med Res Opin. 2021; 37(2): 195–206.
- Ostrowska M, Kubica J, Adamski P, et al. Stratified approaches to antiplatelet therapies based on platelet reactivity testing. Front Cardiovasc Med. 2019; 6: 176.
- Kubica J. Should dual antiplatelet treatment be guided by lipoprotein(a) concentration? Cardiol J. 2024; 31(2): 363–364.
- Kubica J, Adamski P, Dobrzycki S, et al. Cangrelor - Expanding therapeutic options in patients with acute coronary syndrome. Cardiol J. 2024; 31(1): 133–146.
- Kubica J, Adamski P, Ładny JR, et al. Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022. Cardiol J. 2022; 29(4): 540–552.
- Kubica J, Adamski P, Gajda R, et al. Andexanet alfa - Recommendations for clinical use. Multidisciplinary experts' standpoint. Cardiol J. 2023; 30(4): 502–505.
- Kubica J, Adamski P, Buszko K, et al. Rationale and design of the effectiveness of lower maintenanCe dose of ticagrelor early after myocardial infarction (ELECTRA) pilot study. Eur Heart J Cardiovasc Pharmacother. 2018; 4(3): 152–157.
- Kubica J, Adamski P, Buszko K, et al. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Eur Heart J Cardiovasc Pharmacother. 2019; 5(3): 139–148.
- Kubica J, Adamski P, Niezgoda P, et al. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J. 2021; 28(4): 607–614.
- Kubica J, Adamski P, Gorog D, et al. Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiology Journal. 2022; 29(1): 148–153.
- Fox K, Ford I, Steg PG, et al. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008; 372(9641): 817–821.
- Fox K, Ford I, Steg PhG, et al. BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009; 30(19): 2337–2345.
- Fox K, Ford I, Steg PG, et al. SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014; 371(12): 1091–1099.
- Beltrame JF. Ivabradine and the SIGNIFY conundrum. Eur Heart J. 2015; 36(46): 3297–3299.
- Ferrari R, Camici PG, Crea F, et al. Expert consensus document: A 'diamond' approach to personalized treatment of angina. Nat Rev Cardiol. 2018; 15(2): 120–132.
- Wei J, Wu T, Yang Q, et al. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol. 2011; 146(1): 4–12.
- Jiang J, Li Y, Zhou Y, et al. Oral nicorandil reduces ischemic attacks in patients with stable angina: A prospective, multicenter, open-label, randomized, controlled study. Int J Cardiol. 2016; 224: 183–187.
- Horinaka S, Yabe A, Yagi H, et al. JCAD Study Investigators. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J. 2010; 74(3): 503–509.
- Zhu WL, Shan YD, Guo JX, et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J. 2007; 71(6): 826–833.
- IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002; 359(9314): 1269–1275.
- Di Somma S, Liguori V, Petitto M, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther. 1993; 7(1): 119–123.
- Döring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol. 1992; 20 Suppl 3: S74–S81.
- Zhao Y, Peng L, Luo Y, et al. Trimetazidine improves exercise tolerance in patients with ischemic heart disease : A meta-analysis. Herz. 2016; 41(6): 514–522.
- Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 2014; 177(3): 780–785.
- Pavasini R, Camici PG, Crea F, et al. Anti-anginal drugs: Systematic review and clinical implications. Int J Cardiol. 2019; 283: 55–63.
- Belsey J, Savelieva I, Mugelli A, et al. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. Eur J Prev Cardiol. 2015; 22(7): 837–848.
- Bertero E, Heusch G, Münzel T, et al. A pathophysiological compass to personalize antianginal drug treatment. Nat Rev Cardiol. 2021; 18(12): 838–852.